Scholarlink

Background <p>Computed tomography (CT) is as safe as invasive coronary angiography (ICA) in the incidence of major adverse cardiovascular events in patients with atypical chest pain. However, the cost-utility of CT and ICA in healthcare after long-term follow-up is still unknown.</p> Methods <p>A prespecified cost-utility analysis (CUA)&#xa0;of 329 patients with atypical chest pain from a single-centre randomised trial compared CT and ICA. The CUA was conducted from the health sector perspective up to a 3-year follow-up using quality-adjusted life years (QALYs) from the EQ-5D-3L questionnaire. Costs were obtained from each individual’s outpatient and inpatient billing data and included cardiovascular medications, hospitalisations, emergency visits, cardiologist visits, and cardiac examinations. The analysis implemented 500 multiple imputations and 1000 bootstrapping iterations per imputed dataset, followed by calculating the net monetary benefit (NMB).</p> Results <p>There was no significant difference in mean QALYs at either 1-year (CT: 0.69 (95% CI: 0.66–0.72); ICA: 0.71 (95% CI: 0.68–0.74); difference: −0.02 (−0.06 to 0.03)) or 3-year follow-up (CT: 2.09 (95% CI: 2.00–2.17); ICA: 2.11 (95% CI: 2.02–2.19); difference: −0.02 (95% CI: −0.14 to 0.12)), while the mean cost per patient was significantly lower in the CT compared with the ICA at both 1-year (difference (€): −1647.8, 95% CI: −2198.3 to 1093.3) and at 3-year follow-ups (difference (€): −1543.3, 95% CI: −2228.0 to −830.0). At a willingness-to-pay of €20,000/QALY, the mean incremental NMB of CT over ICA was €1256.5 (164.8–2331.8) at 1-year and €1202.0 (95% CI: −1378.7 to −3961) at 3-year follow-ups.</p> Conclusion <p>A CT-first strategy for the management of patients with atypical angina or chest pain was more cost-effective than a direct ICA strategy.</p> Trial registration <p>ClinicalTrials.gov NCT00844220.</p> Key Points <p><Emphasis Type="BoldItalic">Question</Emphasis> <i>What is the cost-effectiveness of using CT compared to invasive coronary angiography (ICA) for diagnosing coronary artery disease in patients with atypical chest pain?</i></p> <p><Emphasis Type="BoldItalic">Findings</Emphasis> <i>A CT-first diagnostic strategy was €1543 less costly per patient over a 3-year follow-up, yielding similar quality-adjusted life years compared to ICA.</i></p> <p><Emphasis Type="BoldItalic">Clinical relevance</Emphasis> <i>CT offers a cost-effective, non-invasive alternative to ICA for patients with atypical chest pain, reducing healthcare costs significantly without compromising patient-reported outcomes or quality of life.</i></p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cost-utility of computed tomography in patients with atypical chest pain clinically referred for invasive coronary angiography: randomised controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月24日

查看全文
  • Maria Bosserdt,
  • Mahmoud Mohamed,
  • Konrad Neumann,
  • Nina Rieckmann,
  • Henryk Dreger,
  • Valentin Brodszky,
  • Stefan Höfer,
  • Thomas Reinhold,
  • Anna-Maria Mielke,
  • Marc Dewey

摘要

Background

Computed tomography (CT) is as safe as invasive coronary angiography (ICA) in the incidence of major adverse cardiovascular events in patients with atypical chest pain. However, the cost-utility of CT and ICA in healthcare after long-term follow-up is still unknown.

Methods

A prespecified cost-utility analysis (CUA) of 329 patients with atypical chest pain from a single-centre randomised trial compared CT and ICA. The CUA was conducted from the health sector perspective up to a 3-year follow-up using quality-adjusted life years (QALYs) from the EQ-5D-3L questionnaire. Costs were obtained from each individual’s outpatient and inpatient billing data and included cardiovascular medications, hospitalisations, emergency visits, cardiologist visits, and cardiac examinations. The analysis implemented 500 multiple imputations and 1000 bootstrapping iterations per imputed dataset, followed by calculating the net monetary benefit (NMB).

Results

There was no significant difference in mean QALYs at either 1-year (CT: 0.69 (95% CI: 0.66–0.72); ICA: 0.71 (95% CI: 0.68–0.74); difference: −0.02 (−0.06 to 0.03)) or 3-year follow-up (CT: 2.09 (95% CI: 2.00–2.17); ICA: 2.11 (95% CI: 2.02–2.19); difference: −0.02 (95% CI: −0.14 to 0.12)), while the mean cost per patient was significantly lower in the CT compared with the ICA at both 1-year (difference (€): −1647.8, 95% CI: −2198.3 to 1093.3) and at 3-year follow-ups (difference (€): −1543.3, 95% CI: −2228.0 to −830.0). At a willingness-to-pay of €20,000/QALY, the mean incremental NMB of CT over ICA was €1256.5 (164.8–2331.8) at 1-year and €1202.0 (95% CI: −1378.7 to −3961) at 3-year follow-ups.

Conclusion

A CT-first strategy for the management of patients with atypical angina or chest pain was more cost-effective than a direct ICA strategy.

Trial registration

ClinicalTrials.gov NCT00844220.

Key Points

Question What is the cost-effectiveness of using CT compared to invasive coronary angiography (ICA) for diagnosing coronary artery disease in patients with atypical chest pain?

Findings A CT-first diagnostic strategy was €1543 less costly per patient over a 3-year follow-up, yielding similar quality-adjusted life years compared to ICA.

Clinical relevance CT offers a cost-effective, non-invasive alternative to ICA for patients with atypical chest pain, reducing healthcare costs significantly without compromising patient-reported outcomes or quality of life.

Graphical Abstract